How Has the Endocrine Testing Market Evolved Historically and What is its Current Size?
The endocrine testing market has seen considerable growth due to a variety of factors.
• The endocrine testing market has shown strong growth in recent years. It is projected to expand from $2.55 billion in 2024 to $2.8 billion in 2025, growing at a compound annual growth rate (CAGR) of 9.8%.
This growth is attributed to the discovery of hormones and endocrine pathways, standardization of diagnostic tests, public health initiatives, and the empowerment and advocacy of patients.
What Is The Projected Growth Of The Endocrine Testing Template Market?
The endocrine testing market is expected to maintain its strong growth trajectory in upcoming years.
• The endocrine testing market is expected to grow steadily, reaching $4.01 billion by 2029 at a CAGR of 9.5%.
Growth is driven by the rising prevalence of endocrine disorders, greater defense spending, an aging population, heightened awareness, and earlier diagnoses. Key trends include advancements in biomarker detection, integration of omics technologies, AI and ML applications, standardization, and collaborative research in translational medicine.
What Are The Key Drivers Fueling Growth In The Endocrine Testing Market?
The growing prevalence of diabetes is expected to drive the growth of the endocrine testing market in the future. Diabetes leads to high blood sugar levels, and its rise is fueled by unhealthy lifestyles, genetic predispositions, and aging populations. Endocrine testing, which includes tests like hemoglobin A1c, fasting plasma glucose, and C-peptide, is critical in diagnosing and managing diabetes. For instance, in June 2024, the NHS reported a significant rise in diabetes cases among individuals under 40, which underscores the alarming increase in diabetes prevalence in younger populations. This trend is driving the growth of the endocrine testing market.
What Are The Principal Market Segments In The Global Endocrine Testing Industry?
The endocrine testing market covered in this report is segmented –
1) By Test Type: Estradiol (E2) Test, Follicle Stimulating Hormone (FSH) Test, Human Chorionic Gonadotropin (hCG) Hormone Test, Luteinizing Hormone (LH) Test, Dehydroepiandrosterone Sulfate (DHEAS) Test, Progesterone Test, Testosterone Test, Thyroid Stimulating Hormone (TSH) Test, Prolactin Test, Other Types
2) By Technology: Tandem Mass Spectrometry, Immunoassay, Monoclonal And Polyclonal Antibody Technologies, Sensor Technology, Clinical Chemistry, Other Technologies
3) By End-User: Hospitals, Clinical Laboratories, Diagnostic Centers, Other End-Users
Subsegments:
1) By Estradiol (E2) Test: Serum Estradiol Test, Urinary Estradiol Test
2) By Follicle Stimulating Hormone (FSH) Test: FSH Serum Test, FSH Urine Test
3) By Human Chorionic Gonadotropin (hCG) Hormone Test: Quantitative hCG Test, Qualitative hCG Test
4) By Luteinizing Hormone (LH) Test: LH Serum Test, LH Urine Test
5) By Dehydroepiandrosterone Sulfate (DHEAS) Test: Serum DHEAS Test, Saliva DHEAS Test
6) By Progesterone Test: Serum Progesterone Test, Urinary Progesterone Test
7) By Testosterone Test: Free Testosterone Test, Total Testosterone Test
8) By Thyroid Stimulating Hormone (TSH) Test: TSH Serum Test, TSH Saliva Test
9) By Prolactin Test: Serum Prolactin Test, Plasma Prolactin Test
10) By Other Types: Cortisol Test, Insulin Test, Growth Hormone (GH) Test, Aldosterone Test
Pre-Book The Endocrine Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Endocrine Testing Market?
Companies in the endocrine testing market are developing point-of-care testing solutions to increase accessibility and efficiency in diagnosing endocrine disorders. For instance, in April 2024, Roche Holding AG, a Swiss pharmaceutical company, launched a point-of-care NT-proBNP test in India. This test aids in the early detection of heart failure in patients with diabetes, allowing clinicians to intervene earlier and improve patient outcomes.
Who Are the Key Players In The Endocrine Testing Market?
Major companies operating in the endocrine testing market are:
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Roche Holding
• Siemens Healthineers
• Quest Diagnostics
• Agilent Technologies Inc.
• PerkinElmer Inc.
• BioMérieux SA
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• SD Biosensor Inc.
• Qiagen N.V.
• Ortho Clinical Diagnostics
• Kronus Inc.
• Randox Laboratories Ltd.
• Fujirebio Diagnostics Inc.
• Inova Diagnostics Inc.
• Sekisui Diagnostics LLC
• Mercodia AB
• ZEUS Scientific Inc.
• IBL International
• Monobind Inc.
• Agilus Diagnostics
• Tosoh Bioscience Inc.
• DiaSorin S.p.A.
What Are The Regional Insights Into The Endocrine Testing Market?
North America was the largest region in the endocrine testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endocrine testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
